Gasporox (GPX) Q3 2025 earnings summary

Executive summary

• Achieved clear recovery and growth in Q3 2025, with revenue up 22% year-over-year to 9,453 KSEK and a positive operating result of 60 KSEK compared to -1,334 KSEK last year.

• Service business and new solutions broadened market potential, with notable expansion in Europe and new product launches targeting food and pharma sectors.

• Opened Lab Luna, a new measurement service lab, formalizing measurement-as-a-service and expanding recurring revenue streams.

Financial highlights

• Q3 2025 revenue: 9,453 KSEK (up from 7,767 KSEK in Q3 2024); operating income: 60 KSEK (from -1,334 KSEK); EBITDA: 1,689 KSEK (from 87 KSEK).

• Cash flow for Q3: -1,819 KSEK (from -2,225 KSEK); cash at period end: 10,490 KSEK (from 8,424 KSEK).

• For the first nine months: revenue 20,281 KSEK (down from 26,097 KSEK), operating result -7,485 KSEK (from -1,098 KSEK), cash flow 3,677 KSEK (from -2,197 KSEK).

• Result per share Q3: -0.03 SEK (from -0.17 SEK); nine months: -0.93 SEK (from -0.18 SEK).

Outlook and guidance

• Focus remains on long-term profitable growth through innovation, service expansion, and customer-driven development.

• New product launches and expanded service offerings expected to drive future growth, especially in pharma and food sectors.